Summary
Nabi Biopharmaceuticals (Nabi) is a a biopharmaceutical company engaged in the development and marketing of vaccines for the treatment of serious medical conditions in the field of nicotine addiction and infectious disease. The company is focused on the development of first and second generation products that address unmet medical needs. The research and development pipeline products of the company includes, several novel vaccines in various stages of development for the treatment of nicotine addition and Grampositive bacterial infections. Currently, the company is engaged in the development of NicVAX (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine to treat nicotine addiction and prevent smoking relapse. Nabi is headquartered at Rockville in Maryland, the US.
Recently, the company initiated a second phase III study for NicVAX as an aid to smoking cessation and longterm abstinence.
Nabi Biopharmaceuticals Key Recent Developments…
Aug 03, 2011: Nabi Biopharmaceuticals Reports Total Revenue Of $3.7m For Q2 2011
May 05, 2011: Nabi Biopharmaceuticals Reports Net Income Of $2m For Q1 2011
Mar 08, 2011: Nabi Biopharmaceuticals Reports Net Loss Of $6.3m For Q4 2010
Nov 03, 2010: Nabi Reports Net Income Of $5.1 Million For Q3 2010
Aug 24, 2010: Nabi Biopharmaceuticals Receives New Patent From US Patent And Trademark Office
This comprehensive SWOT profile of Nabi Biopharmaceuticals provides you an indepth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by Company to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
For more information, please visit:
http://www.aarkstore.com/reports/Nabi-Biopharmaceuticals-NABI-Financial-and-Strategic-SWOT-Analysis-Review-10896.html
Or email us at contact@aarkstore.com or call +918149852585
Related reports
http://www.aarkstore.com/search/viewresults.asp?search=Nabi%20Biopharmaceuticals&PubId=&pagenum=1
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
Nabi Biopharmaceuticals (Nabi) is a a biopharmaceutical company engaged in the development and marketing of vaccines for the treatment of serious medical conditions in the field of nicotine addiction and infectious disease. The company is focused on the development of first and second generation products that address unmet medical needs. The research and development pipeline products of the company includes, several novel vaccines in various stages of development for the treatment of nicotine addition and Grampositive bacterial infections. Currently, the company is engaged in the development of NicVAX (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine to treat nicotine addiction and prevent smoking relapse. Nabi is headquartered at Rockville in Maryland, the US.
Recently, the company initiated a second phase III study for NicVAX as an aid to smoking cessation and longterm abstinence.
Nabi Biopharmaceuticals Key Recent Developments…
Aug 03, 2011: Nabi Biopharmaceuticals Reports Total Revenue Of $3.7m For Q2 2011
May 05, 2011: Nabi Biopharmaceuticals Reports Net Income Of $2m For Q1 2011
Mar 08, 2011: Nabi Biopharmaceuticals Reports Net Loss Of $6.3m For Q4 2010
Nov 03, 2010: Nabi Reports Net Income Of $5.1 Million For Q3 2010
Aug 24, 2010: Nabi Biopharmaceuticals Receives New Patent From US Patent And Trademark Office
This comprehensive SWOT profile of Nabi Biopharmaceuticals provides you an indepth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by Company to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
For more information, please visit:
http://www.aarkstore.com/reports/Nabi-Biopharmaceuticals-NABI-Financial-and-Strategic-SWOT-Analysis-Review-10896.html
Or email us at contact@aarkstore.com or call +918149852585
Related reports
http://www.aarkstore.com/search/viewresults.asp?search=Nabi%20Biopharmaceuticals&PubId=&pagenum=1
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
No comments:
Post a Comment